Atlas Trials

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Clinical trial NCT07594015 · RECRUITING

Trial details

NCT number
NCT07594015
Sponsor
University of Miami
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Endometrial Cancer
Start date
2026-09-01
Primary completion
2031-09-01
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.